Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 2142-2151 |
| Journal | British Journal of Cancer |
| Volume | 111 |
| DOIs | |
| Publication status | Published - 2014 |
| MoE publication type | A1 Journal article-refereed |
Fingerprint
Cite this
}
Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivo. / Winsel, S.; Mäki-Jouppila, Jenni; Tambe, Mahesh; Aure, M.R.; Pruikkonen, Sofia-Maria; Salmela, Anna; Halonen, T.; Leivonen, Suvi; Kallio, Lila; Børresen-Dale, A.-L.; Kallio, M.J. (Corresponding Author).
In: British Journal of Cancer, Vol. 111, 2014, p. 2142-2151.Research output: Contribution to journal › Article › Scientific › peer-review
TY - JOUR
T1 - Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivo
AU - Winsel, S.
AU - Mäki-Jouppila, Jenni
AU - Tambe, Mahesh
AU - Aure, M.R.
AU - Pruikkonen, Sofia-Maria
AU - Salmela, Anna
AU - Halonen, T.
AU - Leivonen, Suvi
AU - Kallio, Lila
AU - Børresen-Dale, A.-L.
AU - Kallio, M.J.
PY - 2014
Y1 - 2014
N2 - Background: Optimal expression and proper function of key mitotic proteins facilitate control and repair processes that aim to prevent loss or gain of chromosomes, a hallmark of cancer. Altered expression of small regulatory microRNAs is associated with tumourigenesis and metastasis but the impact on mitotic signalling has remained unclear. Methods: Cell-based high-throughput screen identified miR-378a-5p as a mitosis perturbing microRNA. Transient transfections, immunofluorescence, western blotting, time-lapse microscopy, FISH and reporter assays were used to characterise the mitotic anomalies by excess miR-378a-5p. Analysis of microRNA profiles in breast tumours was performed. Results: Overexpression of miR-378a-5p induced numerical chromosome changes in cells and abrogated taxol-induced mitotic block via premature inactivation of the spindle assembly checkpoint. Moreover, excess miR-378a-5p triggered receptor tyrosine kinase–MAP kinase pathway signalling, and was associated with suppression of Aurora B kinase. In breast cancer in vivo, we found that high miR-378a-5p levels correlate with the most aggressive, poorly differentiated forms of cancer. Interpretation: Downregulation of Aurora B by excess miR-378a-5p can explain the observed microtubule drug resistance and increased chromosomal imbalance in the microRNA-overexpressing cells. The results suggest that breast tumours may deploy high miR-378a-5p levels to gain growth advantage and antagonise taxane therapy.
AB - Background: Optimal expression and proper function of key mitotic proteins facilitate control and repair processes that aim to prevent loss or gain of chromosomes, a hallmark of cancer. Altered expression of small regulatory microRNAs is associated with tumourigenesis and metastasis but the impact on mitotic signalling has remained unclear. Methods: Cell-based high-throughput screen identified miR-378a-5p as a mitosis perturbing microRNA. Transient transfections, immunofluorescence, western blotting, time-lapse microscopy, FISH and reporter assays were used to characterise the mitotic anomalies by excess miR-378a-5p. Analysis of microRNA profiles in breast tumours was performed. Results: Overexpression of miR-378a-5p induced numerical chromosome changes in cells and abrogated taxol-induced mitotic block via premature inactivation of the spindle assembly checkpoint. Moreover, excess miR-378a-5p triggered receptor tyrosine kinase–MAP kinase pathway signalling, and was associated with suppression of Aurora B kinase. In breast cancer in vivo, we found that high miR-378a-5p levels correlate with the most aggressive, poorly differentiated forms of cancer. Interpretation: Downregulation of Aurora B by excess miR-378a-5p can explain the observed microtubule drug resistance and increased chromosomal imbalance in the microRNA-overexpressing cells. The results suggest that breast tumours may deploy high miR-378a-5p levels to gain growth advantage and antagonise taxane therapy.
U2 - 10.1038/bjc.2014.524
DO - 10.1038/bjc.2014.524
M3 - Article
VL - 111
SP - 2142
EP - 2151
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
ER -